z-logo
Premium
NKp30 ‐ A prospective target for new cancer immunotherapy strategies
Author(s) -
Pinheiro Pedro F.,
Justino Gonçalo C.,
Marques M. Matilde
Publication year - 2020
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15222
Subject(s) - immunotherapy , immunosurveillance , granzyme , chimeric antigen receptor , cancer immunotherapy , pharmacophore , cytotoxic t cell , immunology , antigen , computational biology , biology , cancer research , immune system , perforin , cd8 , bioinformatics , biochemistry , in vitro
Natural killer (NK) cells are an important arm of the innate immune system. They constitutively express the NKp30 receptor. NKp30‐mediated responses are triggered by the binding of specific ligands e.g. tumour cell‐derived B7‐H6 and involve the secretion of cytotoxic mediators including TNF‐α, IFN‐γ, perforins and granzymes. The latter two constitute a target cell‐directed response that is critical in the process of immunosurveillance. The structure of NKp30 is presented, focusing on the ligand‐binding site, on the ligand‐induced structural changes and on the experimental data available correlating structure and binding affinity. The translation of NKp30 structural changes to disease progression is also reviewed. NKp30 role in immunotherapy has been explored in chimeric antigen receptor T‐cell (CAR‐T) therapy. However, antibodies or small ligands targeting NKp30 have not yet been developed. The data reviewed herein unveil the key structural aspects that must be considered for drug design in order to develop novel immunotherapy approaches.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here